Abstract
A major function of the chemokine system is to coordinate the recruitment of leukocytes to specific locations within the tissues. The involvement of chemokine receptors in a multitude of inflammatory diseases, coupled with their belonging to the highly “druggable” GPCR superfamily, makes them excellent candidates for the development of novel drugs by the pharmaceutical industry. Despite descriptions in the literature of many specific small molecule chemokine receptor antagonists, none have yet shown efficacy in the clinical inflammatory setting. In this article, we discuss the successes and failures of chemokine receptor antagonists in the clinic and review a subset of molecules that are documented as having activity at two or more chemokine receptors. It may be that a more permissive approach, targeting several chemokine receptors with a single molecule will provide the next generation of anti-inflammatory drugs.
Keywords: Chemokine receptors, chemokines, GPCRs, antagonism
Current Topics in Medicinal Chemistry
Title: Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?
Volume: 10 Issue: 13
Author(s): James E. Pease and Richard Horuk
Affiliation:
Keywords: Chemokine receptors, chemokines, GPCRs, antagonism
Abstract: A major function of the chemokine system is to coordinate the recruitment of leukocytes to specific locations within the tissues. The involvement of chemokine receptors in a multitude of inflammatory diseases, coupled with their belonging to the highly “druggable” GPCR superfamily, makes them excellent candidates for the development of novel drugs by the pharmaceutical industry. Despite descriptions in the literature of many specific small molecule chemokine receptor antagonists, none have yet shown efficacy in the clinical inflammatory setting. In this article, we discuss the successes and failures of chemokine receptor antagonists in the clinic and review a subset of molecules that are documented as having activity at two or more chemokine receptors. It may be that a more permissive approach, targeting several chemokine receptors with a single molecule will provide the next generation of anti-inflammatory drugs.
Export Options
About this article
Cite this article as:
E. Pease James and Horuk Richard, Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?, Current Topics in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/156802610791561228
DOI https://dx.doi.org/10.2174/156802610791561228 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Stroke Outcomes in Mice Lacking the Genes for Neuronal Heme Oxygenase-2 and Nitric Oxide Synthase
Current Neurovascular Research The Proteasome in Health and Disease
Current Pharmaceutical Design KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Current Pharmaceutical Design High Density Lipoprotein Administration: A New Therapeutic Modality for the Treatment of Cardiovascular Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Electro-Acupuncture Protects Diabetic Nephropathy-Induced Inflammation Through Suppression of NLRP3 Inflammasome in Renal Macrophage Isolation
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Commentary (Brilliant Blue G: What a Little More Colour Can Be)
CNS & Neurological Disorders - Drug Targets Supplementation of Rosemary Leaves (Rosmarinus officinalis) Powder Attenuates Oxidative Stress, Inflammation and Fibrosis in Carbon Tetrachloride (CCl4) Treated Rats
Current Nutrition & Food Science Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond
Current Drug Metabolism